New Research Highlights Emerging MRI Contrast Agent for Bladder Imaging
A new MRI contrast agent may provide a viable non-invasive alternative for the detection of interstitial cystitis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.
Through intravesical contrast-enhanced MRI (ICE-MRI), the dual-component MRI contrast agent LP-20 facilitated enhanced phenotyping differentiation between bladder-centric interstitial cystitis (IC) and endometriosis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.
Researchers found that T1- and T2-weighted ICE-MRI images with LP-20 (Lipella Pharmaceuticals) enabled a wider field of view for pelvic abnormalities as well as visualization of sub-surface lesion depth and wall thickening on the serosal side of the bladder that one cannot see via cystoscopy.
The images reveal greater than 7 mm of bladder wall thickening and luminal side trabeculations for a 69-year-old patient with a urethelial lesion (A and C). A sagittal view for a 35-year-old patient revealed a bladder wall less than 5 mm in thickness. (Images courtesy of the 5th International Consultation on Interstitial Cystitis Japan (ICICJ)).
Designed for interstitial cystitis detection, the LP-20 agent may also facilitate the diagnosis of bladder pain syndrome (BPS), according to Lipella Pharmaceuticals.
“LP-20 provides a valuable tool for phenotyping IC/BPS, potentially streamlining patient identification for clinical trials and improving timely access to effective treatments,” added lead study author Pradeep Tyagi, M.D., an associate professor in the Department of Urology at the University of Pittsburgh Medical Center.
The company added that LP-20, which has been the subject of completed pre-clinical and proof-of-concept human trial research, can also diagnose the progression of bladder cancer to muscle invasive bladder cancer.
References
1. Chancellor M, Moon CH, Chermansky C, Yoshimura N, Kaufman J, Tyagi P. Size-dependent paracellular diffusion into urothelium is embodied by intravesical contrast enhanced magnetic resonance imaging (ICE-MRI). Presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ), August 21-23, Kyoto, Japan.
2. Lipella Pharmaceuticals. Lipella Pharmaceuticals unveils advanced bladder imaging technique at ICICJ conference. BioSpace. Available at https://www.biospace.com/lipella-pharmaceuticals-unveils-advanced-bladder-imaging-technique-at-icicj-conference . Published August 21, 2024. Accessed August 21, 2024.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
